|
|
Article: Novartis Buys Overseas Rights To Genentech's AMD Therapy.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Adding to its already formidable ophthalmology franchise, Novartis AG entered a deal with Genentech Inc. for rights outside North America to the latter's therapy for the wet form of age-related macular degeneration.
The drug, Lucentis (ranibizumab, formerly known as rhuFab V2), is an anti-vascular endothelial growth factor antibody fragment in Phase III trials for AMD, a leading cause of blindness that affects about 1.5 million adults in the U.S.
Basel, Switzerland-based Novartis is buying for an undisclosed sum the development and marketing rights outside the U.S., Canada and Mexico.
Under the terms, South San ...